Publication: Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1.
Accepted Date
2005-04-27
Issued Date
2005-04-27
Copyright Date
2005
Resource Type
Language
eng
ISSN
1475-2875 (electronic)
Rights
Mahidol University
Rights Holder(s)
BioMed Central
Bibliographic Citation
Imwong M, Pukrittayakamee S, Grüner AC, Rénia L, Letourneur F, Looareesuwan S, et al. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J. 2005 Apr 27;4(1):20.
Suggested Citation
Mallika Imwong, มัลลิกา อิ่มวงศ์, Sasithon Pukrittayakamee, Grüner, Anne Charlotte, Rénia, Laurent, Letourneur, Frank, Sornchai Looareesuwan, ศรชัย หลูอารีย์สุวรรณ, White, Nicholas J., Snounou, Georges Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1.. Imwong M, Pukrittayakamee S, Grüner AC, Rénia L, Letourneur F, Looareesuwan S, et al. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J. 2005 Apr 27;4(1):20.. doi:10.1186/1475-2875-4-20 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/697
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1.
Corresponding Author(s)
Abstract
BACKGROUND: The use of antimalarial drug combinations with artemisinin
derivatives is recommended to overcome drug resistance in Plasmodium falciparum.
The fixed combination of oral artemether-lumefantrine, an artemisinin combination
therapy (ACT) is highly effective and well tolerated. It is the only registered
fixed combination containing an artemisinin. The trial presented here was
conducted to monitor the efficacy of the six-dose regimen of
artemether-lumefantrine (ALN) in an area of multi-drug resistance, along the
Thai-Myanmar border.
METHODS: The trial was an open-label, two-arm, randomized study comparing
artemether-lumefantrine and mefloquine-artesunate for the treatment of
uncomplicated falciparum malaria with 42 days of follow up. Parasite genotyping
by polymerase chain reaction (PCR) was used to distinguish recrudescent from
newly acquired P. falciparum infections. The PCR adjusted cure rates were
evaluated by survival analysis.
RESULTS: In 2001-2002 a total of 490 patients with slide confirmed uncomplicated
P. falciparum malaria were randomly assigned to receive artemether-lumefantrine
(n = 245) or artesunate and mefloquine (n = 245) and were followed for 42 days.
All patients had rapid initial clinical and parasitological responses. In both
groups, the PCR adjusted cure rates by day 42 were high: 98.8% (95% CI 96.4,
99.6%) for artemether-lumefantrine and 96.3% (95% CI 93.1, 98.0%) for
artesunate-mefloquine. Both regimens were very well tolerated with no serious
adverse events observed attributable to either combination.
CONCLUSION: Overall, this study confirms that these two artemisinin-based
combinations remain highly effective and result in equivalent therapeutic
responses in the treatment of highly drug-resistant falciparum malaria.